Home » AGEB Journal » Issues » Volume 80" » Fasc.4 - Letters » Article details

Pulmonary actinomycosis coexisting with intestinal tuberculosis as a complication of adalimumab treatment for Crohn's disease

Journal Volume 80 - 2017
Issue Fasc.4 - Letters
Author(s) I. Aleric, D. Katalinic, A. Vcev, M. Brinar
Full article
Full Article
(1) Department of Internal Medicine, School of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia ; (2) Department of Pulmonary Medicine, University Hospital Centre Zagreb, Zagreb, Croatia ; (3) Department of Gastroenterology, University Hospital Centre Zagreb, Zagreb, Croatia

Tumor necrosis factor alpha (TNF-a) blocking agents are highly effective in inducing and mantaining remission in Crohn's disease (CD) (1). However, due to the profound supression of T-cell mediated immunity, opportunistic infections still remain a major concern in this group of patients (2). We would like to draw attention to the unique case of a young patient with a imunomodulator therapy-resistant Crohn's disease treated with adalimumab who developed pulmonary actinomycosis and intestinal tuberculosis despite adequate screening for latent tuberculosis.

© Acta Gastro-Enterologica Belgica.
PMID 29560655